抗瘤自组装多肽RADA-KP10联合RPS6KB1抑制剂特立氟胺治疗原发性肝癌的研究

RPS6KB1 is one of the key effectors within mTOR signaling pathway，and is associated with prognosis of hepatocelluar carcinoma. Teriflunomide, a well-known inhibitor of RPS6KB1 have a strong antitumor effect. Anti-tumor self-assembling peptide RADA-KP10 can inhibit proliferation of tumor cells and promote its apoptosis. It also can prevent solid tumor from angiogenesis. Meanwhile, RADA-KP10 is a great biological slow-release material. This project plans to use RADA-KP10 as a carrier to deliver teriflunomide and construct a novel antitumor slow-release system RADA-KP10/teriflunomide. Combination of RADA-KP10 with teriflunomide can fully display their antitumor effects respectively and exhibit great synergistic effect. So RADA-KP10/teriflunomide system can be used for treatment of hepatocelluar carcinoma and improve survival of patients. This project would partially elucidate the antitumor effects of RADA-KP10/teriflunomide system and potential molecular mechanism by investigating its synergistic effect and imply new potential anti-tumor strategies against hepatocelluar carcinoma.

RPS6KB1是mTOR信号转导通路中的关键效应分子之一，与肝癌预后相关。其抑制剂Teriflunomide具有显著的抗肿瘤生长效应。抗瘤自组装多肽RADA-KP10可抑制肿瘤细胞的增殖，促进肿瘤细胞凋亡，并且具有抑制实体肿瘤血管生成的效应。同时，RADA-KP10是一种良好的生物缓释材料。本项目拟通过使用RADA-KP10作为RPS6KB1抑制剂Teriflunomide的载体，构建新型的抗肿瘤缓释体系RADA-KP10/Teriflunomide，充分发挥二者的抗肿瘤协同效应，用于原发性肝癌的治疗，延长患者生存时间。本课题的实施和完成可以部分阐示RADA-KP10/Teriflunomide缓释体系治疗原发性肝癌的效果以及潜在的分子机制，通过研究其协同抗肿瘤效应，为肝癌治疗提供新的临床思路。

RPS6KB1是mTOR信号转导通路中的关键效应分子之一，与肝癌预后相关。其抑制剂Teriflunomide具有显著的抗肿瘤生长效应。抗瘤自组装多肽RADA-KP10可抑制肿瘤细胞的增殖，促进肿瘤细胞凋亡，并且具有抑制实体肿瘤血管生成的效应。同时，RADA-KP10是一种良好的生物缓释材料。本项目拟通过使用RADA-KP10作为RPS6KB1抑制剂Teriflunomide的载体，构建新型的抗肿瘤缓释体系RADA-KP10/Teriflunomide，充分发挥二者的抗肿瘤协同效应，用于原发性肝癌的治疗，延长患者生存时间。本课题的实施和完成可以部分阐示RADA-KP10/Teriflunomide缓释体系治疗原发性肝癌的效果以及潜在的分子机制，通过研究其协同抗肿瘤效应，为肝癌治疗提供新的临床思路。